RxDoctor Payments Data

Anaid Hernandez-Sanchez, MD

Internal Medicine · Richmond, TXNPI 1871949461

Payments from drug & device makers

$2,021in general payments, 2019–2025

Across 93 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$373
  • Novo Nordisk$251
  • Lilly USA, LLC$166
  • Amgen$154
  • Pfizer$153
  • Exact Sciences$122
  • plus $803 from 19 others

What the payments were for

  • Food & beverage$2,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,021 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$118,731
Medicare patients
346
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide227$251,336
JardianceEmpagliflozin215$179,025
MounjaroTirzepatide89$109,190
TrulicityDulaglutide51$58,270
BiktarvyBictegrav/Emtricit/Tenofov Ala12$54,468
EliquisApixaban52$41,189
VraylarCariprazine Hcl23$34,761
XareltoRivaroxaban51$32,430
FarxigaDapagliflozin Propanediol38$25,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,701
Tresiba Flextouch U-100Insulin Degludec33$22,042
UbrelvyUbrogepant13$19,882
Advair HfaFluticasone Propion/Salmeterol35$16,041
Celecoxib291$14,977
Combivent RespimatIpratropium/Albuterol Sulfate24$11,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$251$251,336227 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Stiolto Respimat$15$202,901262 claims
Lilly USA, LLCMounjaro, Trulicity$166$167,460140 claims
AbbVieVraylar, Ubrelvy$373$54,64336 claims
PfizerEliquis$153$41,18952 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$49$36,10263 claims
Johnson & JohnsonXarelto$11$32,43051 claims
AstraZenecaFarxiga, Symbicort$99$30,96758 claims
NovartisEntresto$101$11,34917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Richmond

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →